68 related articles for article (PubMed ID: 29876623)
1. Consensus Statement on the Outcome of a Workshop on Paediatric Phytotherapy: Rationalising Optimal Dosing for Use in Children by Real-World Data.
Hensel A; Bauer R; Heinrich M; Kraft K
Planta Med; 2023 Dec; 89(15):1442-1443. PubMed ID: 37813355
[No Abstract] [Full Text] [Related]
2. Comparing tamsulosin, silodosin versus silodosin plus tadalafil as medical expulsive therapy for lower ureteric stones: A randomised trial.
Rahman MJ; Faridi MS; Mibang N; Singh RS
Arab J Urol; 2018 Jun; 16(2):245-249. PubMed ID: 29892490
[TBL] [Abstract][Full Text] [Related]
3. [Phosphodiesterase inhibitors for the treatment of benign prostatic hyperplasia].
Zengerling F
Urologe A; 2019 Sep; 58(9):1084-1087. PubMed ID: 31342104
[No Abstract] [Full Text] [Related]
4. [Phytotherapy for benign prostatic hyperplasia].
Zengerling F
Urologe A; 2018 Jul; 57(7):846-849. PubMed ID: 29876623
[No Abstract] [Full Text] [Related]
5. Impact of phytotherapy on utility scores for 5 benign prostatic hyperplasia/lower urinary tract symptoms health states.
Dedhia RC; Calhoun E; McVary KT
J Urol; 2008 Jan; 179(1):220-5. PubMed ID: 18001791
[TBL] [Abstract][Full Text] [Related]
6. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
Yamanishi T; Yasuda K; Kamai T; Tsujii T; Sakakibara R; Uchiyama T; Yoshida K
Int J Urol; 2004 Jul; 11(7):501-9. PubMed ID: 15242359
[TBL] [Abstract][Full Text] [Related]
7. Phytotherapy in the management of benign prostatic hyperplasia.
Lowe FC
Urology; 2001 Dec; 58(6 Suppl 1):71-6; discussion 76-7. PubMed ID: 11750257
[TBL] [Abstract][Full Text] [Related]
8. BPH in 2012: novel agents in treatment of BPH.
Chughtai B; Te A
Nat Rev Urol; 2013 Feb; 10(2):72-3. PubMed ID: 23295239
[No Abstract] [Full Text] [Related]
9. [Established and upcoming new options in medical therapy for benign prostatic hyperplasia].
Schlenker B; Beer AM; Gratzke C; Tilki D; Seitz M; Stief CG; Reich O
MMW Fortschr Med; 2009 Oct; 151(41):33-6. PubMed ID: 19891182
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Novara G; Giannarini G; Alcaraz A; Cózar-Olmo JM; Descazeaud A; Montorsi F; Ficarra V
Eur Urol Focus; 2016 Dec; 2(5):553-561. PubMed ID: 28723522
[TBL] [Abstract][Full Text] [Related]
12. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study.
Ryu YW; Lim SW; Kim JH; Ahn SH; Choi JD
Urol Int; 2015; 94(2):187-93. PubMed ID: 25614155
[TBL] [Abstract][Full Text] [Related]
13. Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms.
De Monte C; Carradori S; Granese A; Di Pierro GB; Leonardo C; De Nunzio C
BMC Urol; 2014 Aug; 14():63. PubMed ID: 25112532
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
